NCT06003751View on ClinicalTrials.gov

A Study of PER-001 in Participants With Diabetic Retinopathy

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

August 5, 2023

Primary Completion Date

April 3, 2025

Study Completion Date

April 30, 2026

Conditions
Diabetic Retinopathy
Interventions
DRUG

PER-001 Intravitreal Implant - Low Dose

PER-001 Low Dose Intravitreal Implant

DRUG

PER-001 Intravitreal Implant - High Dose

PER-001 High Dose Intravitreal Implant

DRUG

PER-001 Intravitreal Implant - Sham

PER-001 Intravitreal Sham

Trial Locations (1)

94158

Perfuse Therapeutics, Inc, San Francisco

Sponsors
All Listed Sponsors
lead

Perfuse Therapeutics, Inc.

INDUSTRY

NCT06003751 - A Study of PER-001 in Participants With Diabetic Retinopathy | Biotech Hunter | Biotech Hunter